Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.

Authors

Byoung Chul Cho

Yonsei Cancer Center, Seoul, South Korea

Byoung Chul Cho , Niels Reinmuth , Alexander Luft , Jorge Alatorre-Alexander , Sarayut Lucien Geater , Dmytro Trukhin , Sang-We Kim , Grygorii Ursol , Maen A. Hussein , Farah Louise Lim , Cheng-Ta Yang , Luiz H. Araujo , Haruhiro Saito , Miriam Marotti , Karen Barrett , Xiaojin Shi , Solange Peters , Edward B. Garon , Tony S. K. Mok , Melissa Lynne Johnson

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Biologic Correlates

Clinical Trial Registration Number

NCT03164616

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9035)

DOI

10.1200/JCO.2022.40.16_suppl.9035

Abstract #

9035

Poster Bd #

Abstract Disclosures

FEATURED

Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.

Authors

Byoung Chul Cho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Clinical Trial Registration Number

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.

Poster

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

Poster

A phase 3, randomized study of first-line durvalumab (D) ± tremelimumab (T) + platinum-based chemotherapy (CT) vs CT alone in extensive disease small-cell lung cancer (ED-SCLC): Caspian.

Poster

A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE).